Literature DB >> 16524710

Variation in lung cancer survival rates between countries: do differences in data reporting contribute?

Claire A Butler1, Karen M Darragh, Graeme P Currie, Wendy J A Anderson.   

Abstract

BACKGROUND: Mortality rates from lung cancer are known to vary considerably between countries. Differences in patients, disease, investigation and treatment are thought to account for some survival shortfalls but it is not known whether differences in collection or processing of data also contribute.
METHODOLOGY: We searched recognised sources where information regarding mortality rates have been published for the United Kingdom, Europe and United States (US). Data regarding patient selection, demographics and mortality rates were extracted.
RESULTS: Published international 5-year survival for patients with lung cancer varies from 5% to 16%. The survival figures quoted in the literature are based on data which varies widely in its collection and statistical analysis and this information is not always in the public domain. Data from the US suggests an overall 5-year survival rate of up to 16% although this figure covers only a quarter of the general population and excludes patients without histological confirmation. Many European countries report higher mortality rates although in most, data includes patients without proven histology. European datasets have variable population coverage.
CONCLUSION: Selective data collection and variable population coverage may account for some of the differences in lung cancer survival between countries. More transparent description of data collection and analysis would be helpful but ideally a uniform method of reporting data is required in order to make valid comparisons in mortality rates.

Entities:  

Mesh:

Year:  2006        PMID: 16524710     DOI: 10.1016/j.rmed.2005.12.006

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  5 in total

1.  Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Ticiana A Leal; Jonathan W Riess; Erin Jensen; Bin Zhao; M Catherine Pietanza; Julie R Brahmer
Journal:  J Clin Oncol       Date:  2021-04-19       Impact factor: 50.717

2.  Prognostic Value of Malic Enzyme and ATP-Citrate Lyase in Non-Small Cell Lung Cancer of the Young and the Elderly.

Authors:  Agnes Csanadi; Claudia Kayser; Marcel Donauer; Vera Gumpp; Konrad Aumann; Justyna Rawluk; Antje Prasse; Axel zur Hausen; Sebastian Wiesemann; Martin Werner; Gian Kayser
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

3.  The Expression of the Ubiquitin Ligase SIAH2 (Seven In Absentia Homolog 2) Is Increased in Human Lung Cancer.

Authors:  Paula Moreno; Maribel Lara-Chica; Rafael Soler-Torronteras; Teresa Caro; Manuel Medina; Antonio Álvarez; Ángel Salvatierra; Eduardo Muñoz; Marco A Calzado
Journal:  PLoS One       Date:  2015-11-18       Impact factor: 3.240

Review 4.  Structure, regulatory factors and cancer-related physiological effects of ADAM9.

Authors:  M A Haoyuan; L I Yanshu
Journal:  Cell Adh Migr       Date:  2020-12       Impact factor: 3.405

5.  Defining timeliness in care for patients with lung cancer: protocol for a scoping review.

Authors:  Adnan Ansar; Virginia Lewis; Christine Faye McDonald; Chaojie Liu; Aziz Rahman
Journal:  BMJ Open       Date:  2020-11-04       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.